» Articles » PMID: 24587111

RNA Aptamer Probes As Optical Imaging Agents for the Detection of Amyloid Plaques

Overview
Journal PLoS One
Date 2014 Mar 4
PMID 24587111
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Optical imaging using multiphoton microscopy and whole body near infrared imaging has become a routine part of biomedical research. However, optical imaging methods rely on the availability of either small molecule reporters or genetically encoded fluorescent proteins, which are challenging and time consuming to develop. While directly labeled antibodies can also be used as imaging agents, antibodies are species specific, can typically not be tagged with multiple fluorescent reporters without interfering with target binding, and are bioactive, almost always eliciting a biological response and thereby influencing the process that is being studied. We examined the possibility of developing highly specific and sensitive optical imaging agents using aptamer technology. We developed a fluorescently tagged anti-Aβ RNA aptamer, β55, which binds amyloid plaques in both ex vivo human Alzheimer's disease brain tissue and in vivo APP/PS1 transgenic mice. Diffuse β55 positive halos, attributed to oligomeric Aβ, were observed surrounding the methoxy-XO4 positive plaque cores. Dot blots of synthetic Aβ aggregates provide further evidence that β55 binds both fibrillar and non-fibrillar Aβ. The high binding affinity, the ease of probe development, and the ability to incorporate multiple and multimodal imaging reporters suggest that RNA aptamers may have complementary and perhaps advantageous properties compared to conventional optical imaging probes and reporters.

Citing Articles

Aptamer Technologies in Neuroscience, Neuro-Diagnostics and Neuro-Medicine Development.

Wang B, Kobeissy F, Golpich M, Cai G, Li X, Abedi R Molecules. 2024; 29(5).

PMID: 38474636 PMC: 10934870. DOI: 10.3390/molecules29051124.


Advances in aptamers against Aβ and applications in Aβ detection and regulation for Alzheimer's disease.

Zheng Y, Zhang L, Zhao J, Li L, Wang M, Gao P Theranostics. 2022; 12(5):2095-2114.

PMID: 35265201 PMC: 8899576. DOI: 10.7150/thno.69465.


Aptamers targeting amyloidogenic proteins and their emerging role in neurodegenerative diseases.

Murakami K, Izuo N, Bitan G J Biol Chem. 2021; 298(1):101478.

PMID: 34896392 PMC: 8728582. DOI: 10.1016/j.jbc.2021.101478.


Role of MicroRNAs, Aptamers in Neuroinflammation and Neurodegenerative Disorders.

Khan I, Preeti K, Fernandes V, Khatri D, Singh S Cell Mol Neurobiol. 2021; 42(7):2075-2095.

PMID: 33934227 PMC: 11421650. DOI: 10.1007/s10571-021-01093-4.


An RNA aptamer with potent affinity for a toxic dimer of amyloid β42 has potential utility for histochemical studies of Alzheimer's disease.

Murakami K, Obata Y, Sekikawa A, Ueda H, Izuo N, Awano T J Biol Chem. 2020; 295(15):4870-4880.

PMID: 32127399 PMC: 7152766. DOI: 10.1074/jbc.RA119.010955.


References
1.
Pirttila T, Kim K, Mehta P, Frey H, Wisniewski H . Soluble amyloid beta-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls. J Neurol Sci. 1994; 127(1):90-5. DOI: 10.1016/0022-510x(94)90140-6. View

2.
Gruber A, Lorenz R, Bernhart S, Neubock R, Hofacker I . The Vienna RNA websuite. Nucleic Acids Res. 2008; 36(Web Server issue):W70-4. PMC: 2447809. DOI: 10.1093/nar/gkn188. View

3.
Ono K, Yamada M . Low-n oligomers as therapeutic targets of Alzheimer's disease. J Neurochem. 2011; 117(1):19-28. DOI: 10.1111/j.1471-4159.2011.07187.x. View

4.
Cheng C, Chen Y, Lennox K, Behlke M, Davidson B . In vivo SELEX for Identification of Brain-penetrating Aptamers. Mol Ther Nucleic Acids. 2013; 2:e67. PMC: 3564417. DOI: 10.1038/mtna.2012.59. View

5.
Kayed R, Head E, Sarsoza F, Saing T, Cotman C, Necula M . Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007; 2:18. PMC: 2100048. DOI: 10.1186/1750-1326-2-18. View